Home LiteratureArticle Details
PMID: 1117460 Published · ppublish English Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.

Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine.

Journal of the National Cancer Institute ·Vol. 54 ·No. 1 ·1975-01-00 ·Pages 69-71

Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ

Abstract

In a randomized, controlled study of 80 patients with advanced colorectal carcinoma, the combination of 5-fluorouracil (5-FU), methyl-1, 3-cis(2-chlorethyl)-1-nitrosourea, and vincristine produced an overall degree to toxicity comparable to that of 5-FU used alone. At 10 weeks, a positive objective response rate of 43.5% was observed with the three-drug combination compared to 19.5% with 5-FU alone (P less than 0.5).

MeSH Terms
Antineoplastic Agents/administration & dosage,adverse effects,therapeutic use Colonic Neoplasms/drug therapy Cyclohexanes/adverse effects,analogs & derivatives,therapeutic use Evaluation Studies as Topic Female Fluorouracil/administration & dosage,adverse effects,therapeutic use Humans Male Middle Aged Nitrosourea Compounds/administration & dosage,adverse effects,therapeutic use Rectal Neoplasms/drug therapy Vincristine/administration & dosage,adverse effects,therapeutic use
Chemicals
Antineoplastic Agents Cyclohexanes Nitrosourea Compounds Vincristine Fluorouracil
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Moertel C G
Schutt A J
Hahn R G
Reitemeier R J
Article Info
Journal
Journal of the National Cancer Institute
Abbr.
J Natl Cancer Inst
ISSN
0027-8874
Published
1975-01-00
Pages
69-71
Language
English
Region
United States
NLM ID
7503089
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com